| Basics |
Fulgent Genetics, Inc.
Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care.
|
| IPO Date: |
September 29, 2016 |
| Sector: |
Healthcare |
| Industry: |
Medical Diagnostics and Research |
| Market Cap: |
$614.66M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.94 | 2.97%
|
| Avg Daily Range (30 D): |
$0.44 | 2.30%
|
| Avg Daily Range (90 D): |
$0.39 | 2.17%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.3M |
| Avg Daily Volume (30 D): |
.29M |
| Avg Daily Volume (90 D): |
.31M |
| Trade Size |
| Avg Trade Size (Sh.): |
64 |
| Avg Trade Size (Sh.) (30 D): |
46 |
| Avg Trade Size (Sh.) (90 D): |
48 |
| Institutional Trades |
| Total Inst.Trades: |
1,685 |
| Avg Inst. Trade: |
$1.87M |
| Avg Inst. Trade (30 D): |
$1.03M |
| Avg Inst. Trade (90 D): |
$1.51M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.02M |
| Avg Closing Trade (30 D): |
$1.06M |
| Avg Closing Trade (90 D): |
$1.64M |
| Avg Closing Volume: |
44.69K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
|
|
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$ 292.45M
|
$ 73.46M
|
$ 76.21M
|
|
Gross Profit
|
$ 113.46M
|
$ 28.35M
|
$ 31.85M
|
|
Net Income / Loss
|
$ -41.87M
|
$ -11.9M
|
$ -6.19M
|
|
Operating Income / Loss
|
$ -71.92M
|
$ -19.8M
|
$ -16.14M
|
|
Cost of Revenue
|
$ 178.99M
|
$ 45.12M
|
$ 44.37M
|
|
Net Cash Flow
|
$ 12.74M
|
$ 12.14M
|
$ -2.9M
|
|
PE Ratio
|
|
|
|
|
